ILK is upregulated in (CML) progenitor and leukemic stem cells especially in patients resistant to the tyrosine kinase inhibitors (TKI) imatinib and dasatinib [14]. This evidence concerns the gene ILK and chronic myelogenous leukemia, BCR-ABL1 positive.